The Food and Drug Administration has approved Foundayo, a new weight loss pill from Eli Lilly. This is an exciting time for the weight loss community, as Foundayo is the second oral GLP-1 medication to hit the market in just a few months, following Novo Nordisk’s Wegovy, which was approved last December.
Foundayo comes in six different doses. Patients usually start with the lowest dose to help minimize side effects. Unlike Wegovy, which must be taken on an empty stomach each morning, Foundayo can be taken at any time throughout the day, making it easier to fit into daily routines.
Cost is always a concern when it comes to medication. The lowest dose of Foundayo is expected to be around $149 per month for those paying out of pocket, similar to Wegovy. Higher doses may go up to $349. There’s uncertainty about how many insurance plans will cover it. Some Medicare patients may see it covered this summer under a Trump administration plan, possibly with copays as low as $50.
Eli Lilly’s CEO, Dave Ricks, highlighted how Foundayo simplifies weight loss management. “It fits right into your daily routine. You just take it with your other medications,” he shared.
The weight loss drug market is booming. New options are emerging, each offering unique benefits, different price points, and varying effectiveness. For instance, Lilly is developing another GLP-1 drug called retatrutide, which showed more weight loss potential in trials compared to existing medications.
However, there’s a notable difference in weight loss efficacy between pills and injections. Foundayo’s clinical trials showed an average weight loss of 12.4% after 72 weeks on the highest dose, which is promising but not as high as the injectable versions like Wegovy and Zepbound. These earlier treatments have shown to produce more significant weight loss, which could sway some patients’ preferences.
Maggie Linton, a 77-year-old who participated in Foundayo’s clinical trial, lost nearly 60 pounds. She experienced improvements in her blood pressure and cholesterol levels. “It made a big difference almost immediately,” she said, although she did regain 10 pounds after the trial ended. Linton is now considering going back on the medication since she still wants to reach her weight goal.
Dr. Jody Dushay, an endocrinologist at Harvard Medical School, expressed some skepticism. Many of her patients transitioning from injections to pills have reported less weight loss than expected. “The jury is still out on what these pills can actually achieve,” she stated, noting that 12% weight loss might seem minimal compared to what can be achieved with injections.
Despite these concerns, the demand for weight loss pills remains high. Novo Nordisk reported that over 170,000 individuals were taking Wegovy by February, reflecting a strong interest in oral options as well. This suggests that while injectable medications are effective, many people are still looking for simpler solutions without the hassle of injections.
In summary, Foundayo’s approval adds another option to the evolving weight loss landscape, providing convenience for some patients. While its efficacy may not surpass that of injectable alternatives, it still presents a viable choice for those seeking to manage obesity with less invasive methods. As research continues and user experiences accumulate, we may see further insights into the effectiveness of these medications.
For more insights on recent findings in weight loss treatments, you can check resources like the CDC or ongoing research studies in the medical field.
